-
公开(公告)号：US10179187B2
公开(公告)日：2019-01-15
申请号：US14098443
申请日：2013-12-05
Applicant: Regents of the University of Minnesota
Inventor： Jafar Golzarian , Lihui Weng
Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.
-
公开(公告)号：US20230095373A1
公开(公告)日：2023-03-30
申请号：US17931465
申请日：2022-09-12
Applicant: Regents of the University of Minnesota
Inventor： Jafar Golzarian , Lihui Weng
Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.
-
公开(公告)号：US20180078661A1
公开(公告)日：2018-03-22
申请号：US15709124
申请日：2017-09-19
Applicant: Regents of the University of Minnesota
Inventor： Lihui Weng , Jafar Golzarian
IPC: A61K49/18 , A61K31/704
CPC classification number: A61K49/1863 , A61K9/0019 , A61K9/1652 , A61K31/137 , A61K31/404 , A61K31/4745 , A61K31/704 , A61K47/38
Abstract: The present disclosure is generally directed to an embolic material which, in some examples, may be in the form of a microsphere or a plurality of microspheres. The embolic material may include carboxymethyl chitosan (CCN) crosslinked with partially oxidized carboxymethyl cellulose (OCMC) and an imaging agent such as at least one of an ethiodized oil, a radiopaque metal, or super paramagnetic iron oxide nanoparticles integrally contained within the microsphere.
-
公开(公告)号：US11439725B2
公开(公告)日：2022-09-13
申请号：US16206199
申请日：2018-11-30
Applicant: Regents of the University of Minnesota
Inventor： Jafar Golzarian , Lihui Weng
Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.
-
公开(公告)号：US20190091368A1
公开(公告)日：2019-03-28
申请号：US16206199
申请日：2018-11-30
Applicant: Regents of the University of Minnesota
Inventor： Jafar Golzarian , Lihui Weng
Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.
-
Patent Agency Ranking
公开(公告)号：US10182979B2
公开(公告)日：2019-01-22
申请号：US15466301
申请日：2017-03-22
Applicant: Regents of the University of Minnesota , EmboMedics, Inc.
Inventor： Lihui Weng , Jafar Golzarian , Omid Souresrafil
Abstract: The present disclosure describes a plurality of microspheres that include carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). The microspheres are biocompatible, bioresorbable, and biodegradable. The microspheres may be used in personal care products, such as, for example, toothpaste, topical pain relief products, topical antibiotic products, skincare products such as anti-wrinkle products, eczema products, skin scrubs, acne cleansers, exfoliators, body washes, soaps, pre-shave creams, or the like.
-
7.发明授权Liquid embolic material including carboxymethyl chitosan crosslinked with carboxymethyl cellulose 有权液体栓塞材料包括与羧甲基纤维素交联的羧甲基壳聚糖公开(公告)号：US08936795B2
公开(公告)日：2015-01-20
申请号：US13720135
申请日：2012-12-19
Applicant: Regents of the University of Minnesota
Inventor： Jafar Golzarian , Lihui Weng
CPC classification number: A61L24/043 , A61L31/041 , A61L31/145 , A61L31/16 , A61L31/18 , A61L2430/36 , A61M5/178 , A61M5/19 , C08L5/08 , C08L1/28
Abstract: A liquid embolic material may include a mixture of a first solution comprising between about 1.2% and about 2.5% weight per volume (w/v) carboxymethyl chitosan (CCN) in a first solvent and a second solution comprising between about 1.2% and about 2.5% w/v oxidized carboxymethyl cellulose (OCMC) in a second solvent. The liquid embolic material may be used to embolize a targeted embolization location by mixing the first solution and the second solution to form a liquid embolic material (or hydrogel precursor material), introducing the hydrogel precursor material to a targeted embolization location within a body of a patient, and allowing the CCN and the OCMC to react to form the hydrogel material and embolize the targeted embolization location.
Abstract translation: 液体栓塞材料可以包括在第一溶剂中包含约1.2％至约2.5％重量/体积（w / v）羧甲基壳聚糖（CCN）的第一溶液和包含约1.2％至约2.5％的第二溶液的混合物 ％w / v氧化的羧甲基纤维素（OCMC）在第二溶剂中。 液体栓塞材料可以用于通过混合第一溶液和第二溶液来栓塞目标栓塞位置以形成液体栓塞材料（或水凝胶前体材料），将水凝胶前体材料引入到体内的目标栓塞位置 患者，并允许CCN和OCMC反应形成水凝胶材料并栓塞目标栓塞位置。
-
公开(公告)号：US20170273888A1
公开(公告)日：2017-09-28
申请号：US15466301
申请日：2017-03-22
Applicant: Regents of the University of Minnesota , EmboMedics, Inc.
Inventor： Lihui Weng , Jafar Golzarian , Omid Souresrafil
CPC classification number: A61K8/736 , A61K8/025 , A61K8/731 , A61K31/745 , A61K2800/28 , A61Q11/00 , A61Q19/00 , A61Q19/007 , A61Q19/08
Abstract: The present disclosure describes a plurality of microspheres that include carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). The microspheres are biocompatible, bioresorbable, and biodegradable. The microspheres may be used in personal care products, such as, for example, toothpaste, topical pain relief products, topical antibiotic products, skincare products such as anti-wrinkle products, eczema products, skin scrubs, acne cleansers, exfoliators, body washes, soaps, pre-shave creams, or the like.
-
9.发明申请LIQUID EMBOLIC MATERIAL INCLUDING CARBOXYMETHYL CHITOSAN CROSSLINKED WITH CARBOXYMETHYL CELLULOSE 有权含有羧甲基纤维素交联羧基甲基纤维素的液体材料公开(公告)号：US20140171907A1
公开(公告)日：2014-06-19
申请号：US13720135
申请日：2012-12-19
Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
Inventor： Jafar Golzarian , Lihui Weng
CPC classification number: A61L24/043 , A61L31/041 , A61L31/145 , A61L31/16 , A61L31/18 , A61L2430/36 , A61M5/178 , A61M5/19 , C08L5/08 , C08L1/28
Abstract: A liquid embolic material may include a mixture of a first solution comprising between about 1.2% and about 2.5% weight per volume (w/v) carboxymethyl chitosan (CCN) in a first solvent and a second solution comprising between about 1.2% and about 2.5% w/v oxidized carboxymethyl cellulose (OCMC) in a second solvent. The liquid embolic material may be used to embolize a targeted embolization location by mixing the first solution and the second solution to form a liquid embolic material (or hydrogel precursor material), introducing the hydrogel precursor material to a targeted embolization location within a body of a patient, and allowing the CCN and the OCMC to react to form the hydrogel material and embolize the targeted embolization location.
Abstract translation: 液体栓塞材料可以包括在第一溶剂中包含约1.2％至约2.5％重量/体积（w / v）羧甲基壳聚糖（CCN）的第一溶液和包含约1.2％至约2.5％的第二溶液的混合物 ％w / v氧化的羧甲基纤维素（OCMC）在第二溶剂中。 液体栓塞材料可以用于通过混合第一溶液和第二溶液来栓塞目标栓塞位置以形成液体栓塞材料（或水凝胶前体材料），将水凝胶前体材料引入到体内的目标栓塞位置 患者，并允许CCN和OCMC反应形成水凝胶材料并栓塞目标栓塞位置。
-
公开(公告)号：US20140099374A1
公开(公告)日：2014-04-10
申请号：US14098443
申请日：2013-12-05
Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
Inventor： Jafar Golzarian , Lihui Weng
CPC classification number: A61L24/08 , A61L24/0015 , A61L2300/406 , A61L2300/622 , A61L2430/36 , Y10T428/2982 , C08L5/08 , C08L1/28
Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.
Abstract translation: 本公开总体上涉及栓塞材料，其在一些实施方案中可以是微球体或多个微球体的形式。 栓塞材料通常包含与羧甲基纤维素（CMC）交联的羧甲基壳聚糖（CCN）。 在一些实施方案中，栓塞材料还可以包含治疗剂，例如多柔比星。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.022 seconds)
